

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) Sheet 1 of 1	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794	
	APPLICANT: Dahl et al	
	FILING DATE: 3/20/2006	GROUP ART UNIT: 1616
	EXAMINER NAME:	
		RECEIVED CENTRAL FAX CENTER

DEC 08 2006

U.S. PATENT DOCUMENTS					
Examiner initials	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS			
Examiner initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/A.P./		GILEAD SCIENCES, INC., "Gilead Sciences to Acquire Triangle Pharmaceuticals for \$464 Million" Gilead to Launch Coviracil in 2003 Will Develop Co-Formulation of Viread and Coviracil", Press Release, 2002	

EXAMINER /Alton Pryor/	DATE CONSIDERED 05/14/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

BEST AVAILABLE COPY

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))

Sheet 1 of 1


ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540,794

APPLICANT: Dahl et al

FILING DATE: 3/20/2006

GROUP ART UNIT: 1616

EXAMINER NAME:



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/A.P./		DE CLERCQ E., "Highlights in the Development of New Antiviral Agents", 2(2): 163-175, MINI REV MED CHEM, 2002	
/A.P./		DE CLERCQ E., "New Developmentss in anti-HIV chemotherapy", 56(1-2): 3-12, Farmaco, 2001	
/A.P./		DE CLERCQ E., "New Development in Anti-HIV Chemotherapy", 8(13):1543-72, CURRENT MEDICINAL CHEMISTRY, 2001	
/A.P./		ISHIDA K, ASAO T., "Self-association and Unique DNA Binding Properties of the Anti-Cancer Agent TAS-103, a Dual Inhibitor of Topoisomerases I and II", 1587(2-3):155-163, BIOCHEM BIOPHYS ACTA, 2002	
/A.P./		LIU ET AL., "Thymidylate Synthase as a Translational Regulator of Cellular Gene Expression.", 1587(2-3):174-182, BIOCHEM BIOPHYS ACTA, 2002	

EXAMINER

/Alton Pryor/

DATE CONSIDERED 05/14/2007

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.